The most used drugs in prostate cancer patients were not further specified LH-RH analogs (n = 32/126, 25.4%), bicalutamide (n = 24/126, 19.1%), leuprorelin (n = 23/126, 18.3%), degarelix (n = 12/126, 9.5%), and abiraterone acetate (n = 10/126, 7.9%). This evidence concerns the gene GNRH1 and Familial prostate cancer.